[go: up one dir, main page]

SI9600169A - Process for preparation of compounds with ace inhibitory effect - Google Patents

Process for preparation of compounds with ace inhibitory effect Download PDF

Info

Publication number
SI9600169A
SI9600169A SI9600169A SI9600169A SI9600169A SI 9600169 A SI9600169 A SI 9600169A SI 9600169 A SI9600169 A SI 9600169A SI 9600169 A SI9600169 A SI 9600169A SI 9600169 A SI9600169 A SI 9600169A
Authority
SI
Slovenia
Prior art keywords
formula
cooh
etooc
compounds
optionally
Prior art date
Application number
SI9600169A
Other languages
Slovenian (sl)
Inventor
Palomo Alberto Coll
Serra Sonia Mortes
Original Assignee
Krka Tovarna Zdravil
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Krka Tovarna Zdravil filed Critical Krka Tovarna Zdravil
Priority to SI9600169A priority Critical patent/SI9600169A/en
Priority to DE19721290A priority patent/DE19721290A1/en
Publication of SI9600169A publication Critical patent/SI9600169A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D495/00Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
    • C07D495/02Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D495/10Spiro-condensed systems
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D217/00Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/22Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the nitrogen-containing ring
    • C07D217/26Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D233/00Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30Oxygen or sulfur atoms
    • C07D233/32One oxygen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K5/00Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/02Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link
    • C07K5/022Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2
    • C07K5/0222Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing at least one abnormal peptide link containing the structure -X-C(=O)-(C)n-N-C-C(=O)-Y-; X and Y being heteroatoms; n being 1 or 2 with the first amino acid being heterocyclic, e.g. Pro, Trp
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02PCLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00Technologies relating to chemical industry
    • Y02P20/50Improvements relating to the production of bulk chemicals
    • Y02P20/55Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Preparation of ACE inhibiting compounds of formula Z(CH2)2CH(COOEt)NHCHMeCOR1 (I) and their salts comprises reaction of Z(CH2)2CH(COOEt)NHCHMeCOOH (II) with a silylating agent (so as to introduce a trimethylsilyl protecting group) in an organic, water-free solvent, and optionally in the presence of a base, to obtain Z(CH2)2CH(COOEt)N(SiMe3)CHMeCOOSiMe3 (III), followed by reaction at -50 to -10 deg C to produce Z(CH2)2CH(COOEt)N(SiMe3)CHMeCOCl (IV), which is then reacted with R1H (where the carboxyl group in R1 may be protected), and optionally deprotection, to give (I). Z = alkyl, aryl or heterocyclyl (preferably Ph); R1 = an amine of formula (a)-(k).

Description

KRKA, tovarna zdravil, p.o.KRKA, Medicines Factory, p.o.

Postopek za pripravo spojin z ACE inhibitornim delovanjemA process for the preparation of compounds with ACE inhibitory activity

Področje tehnike, v katero spada izumFIELD OF THE INVENTION

Predloženi izum je s področja organske kemijske sinteze in se nanaša na postopek za pripravo spojin z ACE inhibitornim delovanjem.The present invention relates to the field of organic chemical synthesis and relates to a process for the preparation of compounds with ACE inhibitory activity.

Tehnični problemA technical problem

Obstajala je potreba po enostavnem, učinkovitem, ekonomičnem in industrijsko primernem postopku za pripravo spojin z ACE inhibitornim delovanjem.There was a need for a simple, effective, economical and industrially appropriate process for the preparation of compounds with ACE inhibitory activity.

Stanje tehnikeThe state of the art

Iz literature so znane mnoge sinteze ACE inhibitorjev. Za ACE inhibitorje, ki imajo gradnik (S,S)-N-(l-etoksikarbonil-3-fenilpropil)-L-alanin (formula II v nadaljevanju), se v praksi najpogosteje uporabljata dva postopka, in sicer postopek reduktivnega aminiranja (EP 12401) ali aktivacija (S,S)-N-(l-etoksikarbonil-3-fenilpropil)-Lalanina (US 4,716,235, US 5,359,086).Many syntheses of ACE inhibitors are known from the literature. For ACE inhibitors having the constituent (S, S) -N- (1-ethoxycarbonyl-3-phenylpropyl) -L-alanine (formula II below), two methods are most commonly used in practice, namely the reductive amination process (EP 12401) or the activation of (S, S) -N- (1-ethoxycarbonyl-3-phenylpropyl) -alanine (US 4,716,235, US 5,359,086).

Pri doslej znanih postopkih poteka aktivacija s tionilkloridom težavno in z nizkimi dobitki (US 4,760,162).Thionyl chloride activation is difficult and low-yield (US 4,760,162) for the known methods.

V EP 84164 je opisan postopek z uporabo (S,S)-N-(l-etoksikarbonil-3-fenilpropil)L-alanina, pri katerem je potrebna izolacija s kolonsko kromatografijo in odcepitev zaščitne skupine s katalitskim hidrogeniranjem.EP 84164 describes a process using (S, S) -N- (1-ethoxycarbonyl-3-phenylpropyl) L-alanine, which requires isolation by column chromatography and cleavage of the protecting group by catalytic hydrogenation.

Opis rešitve tehničnega problema z izvedbenimi primeriDescription of solution to a technical problem with implementation examples

Predmet izuma je postopek za pripravo spojin z ACE inhibitornim delovanjem s formulo IThe subject of the invention is a process for the preparation of compounds with ACE inhibitory activity of formula I

EtOOC MeEtOOC Me

in njihovih farmacevtsko sprejemljivih soli, kjer Z pomeni alkilni, arilni ali heterocikličen ostanek, prednostno fenil, in ima Rx naslednje pomene:and their pharmaceutically acceptable salts, wherein Z is an alkyl, aryl or heterocyclic radical, preferably phenyl, and R x has the following meanings:

'COOH'COOH

HH

COOHCOOH

H /H /

COOH /COOH /

-N-N

N t-ΒιΓ s ) COOHN t-ΒιΓ s ) COOH

Θ' ,COOH označen s tem, da spojino s formulo II"COOH", wherein the compound of formula II

EtOOCEtOOC

MeMe

OHOH

II kjer ima Z zgoraj navedeni pomen, sililiramo z reagentom za sililiranje, ki uvede trimetilsililno zaščitno skupino, v organskem brezvodnem topilu, v danem primeru v prisotnosti baze, pri čemer nastane spojina s formulo IIIII wherein Z has the above meaning, silylates with a silylating reagent introducing a trimethylsilyl protecting group in an organic anhydrous solvent, optionally in the presence of a base, to give the compound of formula III

EtOOC Me 's-N 'OSiMejEtOOC Me 's- N ' OSiMej

ŠiMejShiMei

OOh

III ki jo aktiviramo s sredstvi za pripravo kislinskih kloridov pri temperaturi med -10°C in -50°C v spojino s formulo IVIII which is activated by acid chloride preparation agents at a temperature between -10 ° C and -50 ° C to a compound of formula IV

EtOOC MeEtOOC Me

nato pa spojino IV presnovimo z amino derivati s formulothen compound IV is reacted with amino derivatives of formula

RtH, kjer ima R3 gornji pomen in je karboksilna skupina v R} v danem primeru zaščitena, odstranimo trimetilsililno skupino in v danem primeru ostale prisotne zaščitne skupine ter dobljene spojine s formulo I na običajen način prevedemo v njihove farmacevtsko sprejemljive soli.R t H, wherein R 3 have the above meaning, and is a carboxyl group in R} is an optionally protected, remove a trimethylsilyl group and optionally the other protecting groups present, and the resulting compound of formula I in the customary manner into their pharmaceutically acceptable salts.

Farmacevtsko sprejemljive soli so npr. maleat, sulfat, fosfat.Pharmaceutically acceptable salts are e.g. maleate, sulfate, phosphate.

Prednostno organsko topilo je diklorometan.Preferably the organic solvent is dichloromethane.

Prednosten reagent za sililiranje je trimetilklorsilan, v poštev pa pridejo tudi trimetilsilazan (CH3)3SiNHSi(CH3)3, dimetildiklorsilan Cl2Si(CH3)2 ali trimetilsililester trifluorometansulfonske kisline F3C-SO3Si(CH3)3.A preferred reagent for silylation is trimethylchlorosilane, applicable also comes trimetilsilazan (CH 3) 3 SiNHSi (CH 3) 3, dimetildiklorsilan Cl 2 Si (CH 3) 2, trimethylsilyl trifluoromethanesulfonic acid F 3 C-SO 3 Si (CH 3) 3 .

Kot bazo lahko uporabimo trietilamin.Triethylamine can be used as the base.

Kot sredstvo za pripravo kislinskih kloridov prednostno uporabimo tionilklorid.Thionyl chloride is preferably used as acid chloride preparation agent.

Karboksilna skupina v Rx je lahko zaščitena, in to z znanimi zaščitnimi skupinami.The carboxyl group in R x may be protected by known protecting groups.

Prednostno delamo pri temperaturi od -20°C do -25°C.Preferably, the temperature is -20 ° C to -25 ° C.

Zaradi uporabe sililimega sredstva, ki uvede trimetilsililno zaščito, so dobitki reakcije zelo visoki in tudi ne dobimo zasmoljenih produktov, to sredstvo pa se da reciklirati.Due to the use of a silylime agent which introduces trimethylsilyl protection, the yields of the reaction are very high and the products obtained are not desalted, and this product is recyclable.

Reakcija je selektivna. Amino in karboksi skupina se hkrati zaščitita. V primeru uporabe trimetilklorsilana kot sililirnega sredstva in tionilklorida kot aktivacijskega sredstva dobimo pri aktivaciji v spojino IV stranski produkt trimetilklorsilan, ki v sledeči reakciji z amino derivati le-te zaščiti, to pa je še dodatna prednost postopkaThe reaction is selective. The amino and carboxy groups are protected at the same time. In the case of the use of trimethylchlorosilane as a silylating agent and thionyl chloride as the activating agent, by-product activation of compound IV gives trimethylchlorosilane, which in the subsequent reaction with the amino derivatives thereof, protects it, which is an additional advantage of the process

Izum natančneje opisujemo, nikakor pa ga ne omejujemo z naslednjimi primeri.The invention is described in more detail, but in no way limited by the following examples.

PrimeriExamples

Sinteza fSVl-{N-[l-fetoksikarbonin-3-fenilpropil]-L-alanil}-L-prolin maleataSynthesis of fSVl- {N- [1-Fetoxycarbonin-3-phenylpropyl] -L-alanyl} -L-proline maleate

K raztopini 1,4 g (S,S)-N-(l-etoksikarbonil-3-fenilpropil)-L-alanina v 25 ml diklorometana pri -10 do -15°C dodamo 1,27 ml trimetilklorsilana in 1,38 ml trietilamina ter mešamo 15 minut. K zmesi nato dodamo 0,36 ml SOC12 v 4 ml diklorometana in mešamo dodatnih 20 minut, zatem pa dodamo 0,58 g L-prolina in 0,7 ml trietilamina. Zmes mešamo pri -20 do -25°C 67 ur. Hlapne komponente oddestiliramo pri znižanem tlaku. Na preostanek nalijemo raztopino 4,5 g NaCl v 15 ml H2O in 5 ml etil acetata. S 33% NaOH uravnamo pH na 4,24 in ekstrahiramo. Po ločitvi organsko fazo sušimo z Na2SO4, filtriramo in dodamo 0,7 g maleinske kisline v 4 ml etil acetata. Nastalo suspenzijo mešamo pri sobni temperaturi 20 minut. Po filtraciji dobimo 2,1 g produkta s tal. 142 do 144°C.To a solution of 1.4 g (S, S) -N- (1-ethoxycarbonyl-3-phenylpropyl) -L-alanine in 25 ml of dichloromethane at -10 to -15 ° C was added 1.27 ml of trimethylchlorosilane and 1.38 ml. triethylamine and stirred for 15 minutes. To the mixture was then added 0.36 ml of SOCl 2 in 4 ml of dichloromethane and stirred for an additional 20 minutes, then 0.58 g of L-proline and 0.7 ml of triethylamine were added. The mixture was stirred at -20 to -25 ° C for 67 hours. The volatile components are distilled off under reduced pressure. Pour a solution of 4.5 g of NaCl into 15 ml of H 2 O and 5 ml of ethyl acetate. The pH was adjusted to 4.24 with 33% NaOH and extracted. After separation, the organic phase was dried with Na 2 SO 4 , filtered and 0.7 g of maleic acid was added to 4 ml of ethyl acetate. The resulting suspension was stirred at room temperature for 20 minutes. Filtration gave 2.1 g of the product from the ground. 142 to 144 ° C.

Primer 2Example 2

Sinteza sulfata (3aS.7aS)-l-{N-[l-(S)-(etoksikarbonil)-3-fenilpropill-Salanil}oktahidroindol-2-(S)-karboksilne kislineSynthesis of sulphate (3aS.7aS) -1- {N- [1- (S) - (ethoxycarbonyl) -3-phenylpropyl-salanyl} octahydroindole-2- (S) -carboxylic acid

0,9 g (2S,3aS,7aS)-oktahidro-lH-indol-2-karboksilne kisline v 25 ml diklorometana dodamo 0,74 ml trietilamina in 0,66 ml trimetilklorsilana ter mešamo pri sobni temperaturi 1,5 do 2 uri. Medtem pripravimo raztopino 1,4 g (S,S)-N-(l-etoksikarbonil3-fenilpropil)alanina v 25 ml diklorometana, ohladimo na -10 do -15°C in dodamo 1,27 ml trimetilklorsilana in 1,38 ml trietilamina. Po 15 minutah dodamo 0,36 ml SOC12 v 4 ml diklorometana in mešamo še 90 minut, nato pa dodamo prej pripravljen sililni ester (2S,3aS,7aS)-oktahidro-lH-indol-2-karboksilne kisline. Zmes mešamo 22 ur pri sobni temperaturi. Dodamo 3 g NaCl v 10 ml vode in uravnamo pH s 33% NaOH na 0,88. Organski fazi ponovno dodamo 3 g NaCl v 10 ml vode in uravnamo pH s 33% NaOH na 4,22. Organsko fazo oddestiliramo pri znižanem tlaku, na preostanek pa nalijemo 30 ml vode in 15 ml metil t-butil etra. V organsko fazo dodamo 13 g silikagela, 1,5 g aktivnega oglja in mešamo 90 minut. Filtriramo preko Celita®, filtrat ohladimo na -10°C in dokapavamo 0,14 ml 96% H2SO4 v 3,5 ml metil t-butil etra. Mešamo še 3 ure in odfiltriramo 2,04 g produkta s tal. 102 do 106°C in m/z = 430 (M+).0.9 g (2S, 3aS, 7aS) -octahydro-1H-indole-2-carboxylic acid in 25 ml of dichloromethane was added 0.74 ml of triethylamine and 0.66 ml of trimethylchlorosilane and stirred at room temperature for 1.5 to 2 hours. Meanwhile, prepare a solution of 1.4 g (S, S) -N- (1-ethoxycarbonyl3-phenylpropyl) alanine in 25 ml of dichloromethane, cool to -10 to -15 ° C and add 1.27 ml of trimethylchlorosilane and 1.38 ml of triethylamine . After 15 minutes, 0.36 ml of SOCl 2 in 4 ml of dichloromethane was added and stirred for a further 90 minutes, and then the (2S, 3aS, 7aS) -octahydro-1H-indole-2-carboxylic acid silyl ester was added. The mixture was stirred for 22 hours at room temperature. Add 3 g of NaCl in 10 ml of water and adjust the pH from 33% NaOH to 0.88. 3 g of NaCl in 10 ml of water are again added to the organic phase and the pH is adjusted from 33% NaOH to 4.22. The organic phase was distilled off under reduced pressure, and 30 ml of water and 15 ml of methyl t-butyl ether were poured into the residue. To the organic phase was added 13 g of silica gel, 1.5 g of activated carbon and stirred for 90 minutes. Filtered through Celite®, the filtrate was cooled to -10 ° C and 0.14 ml of 96% H 2 SO 4 was added dropwise to 3.5 ml of methyl t-butyl ether. The mixture was stirred for a further 3 hours and 2.04 g of the product was filtered off the soil. 102 to 106 ° C and m / z = 430 (M + ).

Primer 3Example 3

Sinteza {2S-[l[R*(R*)],2o!.3aQ:.7aj3]}-l-{2-[fl-(etoksikarbonil)-3fenilpropil]amino]-l-oksopropil}oktahidro -lH-indol-2-karboksilne kislineSynthesis of {2S- [1 [R * (R *)], 2 O .3aQ: 7aj3]} - 1- {2- [fluoro (ethoxycarbonyl) -3phenylpropyl] amino] -1-oxopropyl} octahydro -1H- indole-2-carboxylic acids

Raztopino 1,4 g (S,S)-N-(l-etoksikarbonil-3-fenilpropil)alanina v 25 ml diklorometana ohladimo na -10 do -15°C ter dodamo 1,27 ml trimetilklorsilana in 1,38 ml trietilamina. Mešamo 15 minut in dodamo 0,36 ml SOC12 v 4 ml diklorometana, mešamo dodatnih 20 minut, zatem pa dodamo 0,85 g (2S,3aR,7aS)-oktahidro-lHindol-2-karboksilne kisline in 0,7 ml trietilamina. Pri -20 do -25°C mešamo 20 ur ter še 22 ur pri sobni temperaturi. Po dodatku 3 g NaCl v 10 ml vode uravnamo pH s 33% NaOH na 8,5 do 9, fazi ločimo in organsko fazo speremo z raztopino 4,5 g NaCl v 15 ml vode. Fazi ločimo in uravnamo pH združenih vodnih faz s 35% HC1 na 4,30. Ekstrahiramo z diklorometanom (2 x 25 ml), fazi ločimo, organsko fazo oddestiliramo pri znižanem tlaku, na preostanek pa nalijemo metil t-butil eter in odfiltriramo 1,98 g produkta. Surov produkt očistimo s preobaijanjem iz vročega etanola in vode. Ko se suspenzija ohladi, odfiltriramo produkt s tal. 122 do 124°C in m/z = 431 (M+ + 1).A solution of 1.4 g of (S, S) -N- (1-ethoxycarbonyl-3-phenylpropyl) alanine in 25 ml of dichloromethane was cooled to -10 to -15 ° C and 1.27 ml of trimethylchlorosilane and 1.38 ml of triethylamine were added. Stirred for 15 minutes and added 0.36 ml of SOCl 2 in 4 ml of dichloromethane, stirred for an additional 20 minutes, then added 0.85 g (2S, 3aR, 7aS) -octahydro-1Hindole-2-carboxylic acid and 0.7 ml of triethylamine . The mixture is stirred at -20 to -25 ° C for 20 hours and at room temperature for 22 hours. After the addition of 3 g of NaCl in 10 ml of water, the pH was adjusted from 33% NaOH to 8.5 to 9, the phase was separated and the organic phase was washed with a solution of 4.5 g of NaCl in 15 ml of water. The phases were separated and the pH of the combined aqueous phases was adjusted from 35% HCl to 4.30. It was extracted with dichloromethane (2 x 25 ml), the phase separated, the organic phase was distilled off under reduced pressure, and methyl t-butyl ether was poured onto the residue and 1.98 g of product was filtered off. The crude product is purified by digestion with hot ethanol and water. When the suspension cools, filter the product from the ground. 122 to 124 ° C and m / z = 431 (M + + 1).

ZaFor

KRKA, tovarna zdravil, p.o.:KRKA, medicines factory, p.o .:

UG-ILMs/, C' : KUG-ILMs /, C ': K

Claims (4)

PATENTNI ZAHTEVKIPATENT APPLICATIONS 1. Postopek za pripravo spojin z ACE inhibitomim delovanjem s formulo IA process for the preparation of compounds with ACE inhibitory activity of formula I EtOOC Me in njihovih farmacevtsko sprejemljivih soli, kjer Z pomeni alkilni, arilni ali heterocikličen ostanek, prednostno fenil, in ima Rx naslednje pomene:EtOOC Me and their pharmaceutically acceptable salts, wherein Z is an alkyl, aryl or heterocyclic radical, preferably phenyl, and R x has the following meanings: / N V-cooh / N V-cooh nrv/ COOH nrv / COOH 1 >-<COOH Me'NV 1> - <COOH Me ' NV H H 1 c i 1 c i 1 / COOH i 1 / COOH i Ct>,COOH Ct> , COOH
H /H / -COOH .iCOOH označen s tem, da spojino s formulo II-COOH .iCOOH characterized in that the compound of formula II EtOOC Me kjer ima Z zgoraj navedeni pomen, sililiramo z reagentom za sililiranje, ki uvede trimetilsililno zaščitno skupino, v organskem brezvodnem topilu, v danem primeru v prisotnosti baze, pri čemer nastane spojina s formulo IIIEtOOC Me where Z has the above meaning, is silylated with a silylating reagent introducing a trimethylsilyl protecting group, in an organic anhydrous solvent, optionally in the presence of a base, to give the compound of formula III EtOOC MeEtOOC Me Z/^X^N4^yOSiMe3 1 oZ / ^ X ^ N 4 ^ y OSiMe 3 1 o SiMej ki jo aktiviramo s sredstvi za pripravo kislinskih kloridov pri temperaturi med -10°C in -50°C v spojino s formulo IVSiMe which is activated by acid chloride preparation agents at a temperature between -10 ° C and -50 ° C to a compound of formula IV EtOOC Me nato pa spojino IV presnovimo z amino derivati s formuloEtOOC Me is then reacted with the IV derivatives of the formula R^, kjer ima Rt gornji pomen in je karboksilna skupina v R1 v danem primeru zaščitena, odstranimo trimetilsililno skupino in v danem primeru ostale prisotne zaščitne skupine ter dobljene spojine s formulo I na običajen način prevedemo v njihove farmacevtsko sprejemljive soli.R 4, wherein R t is of the above meaning and the carboxyl group in R 1 is optionally protected, the trimethylsilyl group is removed and optionally the remaining protecting groups present and the compounds of formula I obtained are conveniently converted into their pharmaceutically acceptable salts.
2. Postopek po zahtevku 1, označen s tem, da ga izvedemo v diklorometanu kot organskem topilu.A process according to claim 1, characterized in that it is carried out in dichloromethane as an organic solvent. 3. Postopek po zahtevku 1, označen s tem, da kot reagent za sililiranje uporabimo trimetilklorsilan, trimetilsilazan (CH3)3SiNHSi(CH3)3, dimetildiklorsilan Cl2Si(CH3)2 ali trimetilsililester trifluorometansulfonske kisline F3C-SO3Si(CH3)3, prednostno trimetilklorsilan.Process according to Claim 1, characterized in that trimethylchlorosilane, trimethylsilazane (CH 3 ) 3 SiNHSi (CH 3 ) 3 , dimethyldichlorosilane Cl 2 Si (CH 3 ) 2 or trimethylsilylester trifluoromethanesulfonic acid F 3 C-SO is used as a silylating reagent. 3 Si (CH 3 ) 3 , preferably trimethylchlorosilane. 4. Postopek po zahtevku 1, označen s tem, da ga izvedemo pri temperaturi med -20°C in-25°C.Process according to claim 1, characterized in that it is carried out at a temperature between -20 ° C and -25 ° C.
SI9600169A 1996-05-22 1996-05-22 Process for preparation of compounds with ace inhibitory effect SI9600169A (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
SI9600169A SI9600169A (en) 1996-05-22 1996-05-22 Process for preparation of compounds with ace inhibitory effect
DE19721290A DE19721290A1 (en) 1996-05-22 1997-05-21 ACE-inhibiting substituted alanyl-derivatives of e.g. proline preparation

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SI9600169A SI9600169A (en) 1996-05-22 1996-05-22 Process for preparation of compounds with ace inhibitory effect

Publications (1)

Publication Number Publication Date
SI9600169A true SI9600169A (en) 1997-12-31

Family

ID=20431852

Family Applications (1)

Application Number Title Priority Date Filing Date
SI9600169A SI9600169A (en) 1996-05-22 1996-05-22 Process for preparation of compounds with ace inhibitory effect

Country Status (2)

Country Link
DE (1) DE19721290A1 (en)
SI (1) SI9600169A (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2289060T3 (en) * 2002-01-30 2008-02-01 Les Laboratoires Servier PROCESS FOR THE PREPARATION OF HIGH PURITY PERINDOPRILE AND USEFUL INTERMEDIATES IN ITS SYNTHESIS.
ATE395913T1 (en) 2003-02-28 2008-06-15 Servier S A Lab METHOD FOR PRODUCING PERINDOPRIL
SI21704A (en) * 2004-01-14 2005-08-31 Lek Farmacevtska Druzba Dd New crystal form of perindopril, procedure of its preparation, pharmaceutical preparations containing this form and their application in treatment of hypertensia
PL367931A1 (en) * 2004-05-12 2005-11-14 Instytut Farmaceutyczny Method for manufacture of 2-[n-[(s)-1- etoxycarbonyl-3-phenyl propyl]-(s)-alanyl] -(1s,3s,5s)-2-azabicyclo [3.3.0] octane-3-carboxylic acid
SI21800A (en) * 2004-05-14 2005-12-31 Krka, Tovarna Zdravil, D.D., Novo Mesto New procedure of synthesis of perindopril

Also Published As

Publication number Publication date
DE19721290A1 (en) 1997-12-11

Similar Documents

Publication Publication Date Title
Barlos et al. Efficient" one-pot" synthesis of N-tritylamino acids
US4618708A (en) Amino acid derivative
CA1205476A (en) Substituted acyl derivatives of octahydro-1h-indole-2- carboxylic acids
US4885283A (en) Phosphinic acid derivatives
CN100503568C (en) Process for the preparation of perindopril, its analgous compounds and salts therof using 2,5 dioxo-oxazolidine intermediate compounds
CA2125080A1 (en) Peptidic phosphinyloxymethyl ketones as interleukin-1beta-converting enzyme inhibitors
US5750555A (en) Bis-indolyl maleinimide or indolopyrrolo carbazole containing an amino acid as PKC inhibitors
KR0121793B1 (en) L-proline derivatives, their preparation and biological applications
SI9600169A (en) Process for preparation of compounds with ace inhibitory effect
EP4009962A1 (en) Compositions of trofinetide
JPS61100564A (en) Peptide-substituted heterocyclic immunostimulants
US4698442A (en) ω-Guanidino-substituted-α-amino acids
AU2004270429B2 (en) Novel method for the synthesis of perindopril and the pharmaceutically-acceptable salts thereof
CA2169335A1 (en) Production of aldehyde derivatives
US4325886A (en) Optical resolution of acylthiopropionic acid
KR100297180B1 (en) Phospholipid derivatives and preparation methods thereof
US3891692A (en) N-(cyclopropylalkoxycarbonyl)amino acids
CA1304388C (en) Process of preparing carboxyalkyl dipeptides
JPH11509850A (en) Method for producing dolastatin 15 and intermediates thereof
JPH049800B2 (en)
Elmore et al. Thioesters of amino acid derivatives as thioacylating agents in thiopeptide synthesis
Houssin et al. Aminoalkyl derivatives of 2, 4′‐bithiazole‐4‐carboxylic acid, the intercalating part of bleomycin
SI21507A (en) Procedure of preparation of compounds with ace inhibition effect
SU664560A3 (en) Method of obtaining peptides or salts thereof
CA2015827A1 (en) Amino acid derivatives possessing renin-inhibitory activities